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The role of the endothelium in protecting from chronic liver disease and TGFβ-mediated
fibrosis remains unclear. Here we describe how the endothelial transcription factor
ETS-related gene (ERG) promotes liver homoeostasis by controlling canonical TGFβ-SMAD
signalling, driving the SMAD1 pathway while repressing SMAD3 activity. Molecular analysis
shows that ERG binds to SMAD3, restricting its access to DNA. Ablation of ERG expression
results in endothelial-to-mesenchymal transition (EndMT) and spontaneous liver
fibrogenesis in EC-specific constitutive hemi-deficient (ErgcEC-Het) and inducible homozygous
deficient mice (ErgiEC-KO), in a SMAD3-dependent manner. Acute administration of the
TNF-α inhibitor etanercept inhibits carbon tetrachloride (CCL4)-induced fibrogenesis in an
ERG-dependent manner in mice. Decreased ERG expression also correlates with EndMT in
tissues from patients with end-stage liver fibrosis. These studies identify a pathogenic
mechanism where loss of ERG causes endothelial-dependent liver fibrogenesis via regulation
of SMAD2/3. Moreover, ERG represents a promising candidate biomarker for assessing
EndMT in liver disease.
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Chronic liver disease (CLD) is an increasing global healthburden; in the UK, liver disease is the fifth biggest cause ofmortality with rates doubling from 1991 to 20071. CLD
can be triggered by numerous factors including diet, alcohol, viral
infection and genetic disorders, which share common features
including excessive inflammation2, dysregulated transforming
growth factor (TGFβ) signalling3 and dramatic disruption in the
vascular architecture of the liver4, 5. Recent studies have revealed
that disruption of endothelial cell (EC) homoeostasis can initiate
tissue damage and fibrosis6–8. Notably, EC have been shown to
lose their lineage-specific markers and morphology and acquire a
mesenchymal-like phenotype in a process termed endothelial-to-
mesenchymal transition (EndMT)9. EndMT is associated
with human pathologies such as early vein-graft rejection10
and atherosclerosis11, where it correlates with disease severity.
EndMT has been shown to be induced by TGFβ in vitro and
in vivo10, 12, and to be enhanced by inflammatory mediators
including TNF-α13, 14.
Canonical TGFβ/bone morphogenetic protein (BMP) signal-
ling can activate two opposing signalling cascades, maintaining
homoeostasis via phosphorylation of transcription factors
SMAD1/5/8, while instigating pro-fibrotic signalling via phos-
phorylation of SMAD2/315 (Supplementary Fig. 1). In EC, TGFβ
isoforms activate SMAD1/5/8 signalling via the receptor ACVRL1
and its co-factor endoglin (ENG)16. BMP ligand-BMP receptor
(BMPR) and TGFβ-ACVRL1 interactions selectively induce
SMAD1 phosphorylation and directly inhibit TGFβ-ALK5-
SMAD3-mediated transcription17. Importantly, TGF-β-induced
signalling is influenced by cross-talk with multiple pathways and
by lineage-specific co-factors18. Thus, regulation of the balance
between SMAD1 and SMAD3 signalling is crucial in maintaining
EC homeostasis19, 20.
The ETS transcription factor family plays important roles in
vascular development and angiogenesis21. The ETS-related gene
(ERG) is the most abundant ETS factor in adult ECs and is
essential for endothelial lineage identity; indeed, it is one of only
three transcription factors required for reprogramming of pro-
genitors to endothelium22. ERG is crucial for embryonic devel-
opment and vascular stability23, 24, angiogenesis25 and protection
from vascular inflammation26, 27. ERG exerts its pro-homoeo-
static, anti-inflammatory function in ECs by driving expression of
homoeostatic genes while repressing pro-inflammatory gene
expression and inhibiting cytokine-induced EC activation21, 28. In
turn, pro-inflammatory molecules TNF-α26 and lipopoly-
saccharides (LPS)27 induce a significant loss in ERG expression in
ECs, suggesting that regulation of ERG expression is key to
control of the balance between endothelial homoeostasis and
inflammatory signalling.
In this study, we show that ERG maintains the homoeostatic
balance of SMAD-dependent signalling in the endothelium, by
promoting the SMAD1 pathway while repressing SMAD2/3
activity. We show that loss of ERG in vitro and in vivo results in
spontaneous EndMT which is dependent on enhanced SMAD2/3
activity. TNF-α blockade protects ERG expression and reduces
phosphorylation of SMAD2/3 in an acute model of liver fibrosis,
but is ineffective in ERG hemi-deficient mice. Finally, we show
that ERG expression is lost in liver EC from cirrhotic patients
with fibrosis related to alcoholic liver disease (ALD) or primary
biliary cirrhosis (PBC) and inversely correlates with increased
markers of EndMT. Therefore, this study identifies a central role
for ERG in regulating EC canonical TGFβ-SMAD signalling to
prevent EndMT and ultimately tissue fibrogenesis. Loss of
endothelial ERG expression is an early, causative event during
tissue fibrogenesis, linked to inflammatory pathways, which can
be targeted therapeutically.
Results
ERG regulates SMAD signalling in EC and protects from
EndMT. Gene ontology analysis of transcriptome data from
ERG-deficient human umbilical cord endothelial cells
(HUVEC)25 identified 41 target genes associated with TGFβ/BMP
canonical signalling as putative ERG targets (Supplementary
Table 1; Fig. 1a). qRT-PCR validation of selected hits and other
relevant genes is show in Fig. 1b. Inhibition of ERG in HUVEC
caused a reduction in gene expression of SMAD1, ACVRL1
(ALK1), endoglin (ENG) and inhibitor of DNA binding 1 (ID1).
This response was mirrored by elevated expression of TGFβ
isoforms 1 and 2 and of mesenchymal genes collagen A1
(Col1A1), smooth muscle actin (SMA) and smooth muscle cal-
ponin (CNN1). Gene expression levels of other signalling SMADs
(5 and 8) were not significantly changed in ERG-deficient cells
(Supplementary Fig. 2A). A second siRNA (#2) targeting ERG
generated a similar mRNA profile (Supplementary Fig. 2B).
Protein levels of SMAD1 and its associated proteins, ENG and
ID1, were also significantly reduced (Fig. 1c, d and Supplemen-
tary Fig. 2C). Loss of SMAD1 expression was confirmed in vivo,
within liver tissue from EC-specific constitutive Erg hemi-
deficient mice23 (ErgcEC-Het; Fig. 1e; arrows). Gene and protein
expression levels of SMAD3 and its receptor TGFBR1/ALK5 were
unaffected (Fig. 1b–d). However, there was increased expression
of the downstream targets SMA (Fig. 1d) and TGFβ2 (Fig. 1f).
Furthermore, immunofluorescence microscopy revealed
increased TGFβ2 expression in ERG-deficient EC in vitro
(Fig. 1g) and in large blood vessels in the liver of ErgcEC-Het mice
in vivo (Fig. 1h; arrows). The profile of ERG-deficient cells,
namely marked upregulation of mesenchymal markers and
downregulation of endothelial lineage identity markers, together
with transition from the typical rounded/cobblestone morphology
to a distinct mesenchymal-like shape25, suggest that the cells are
undergoing EndMT. Thus, ERG reciprocally regulates TGFβ/
BMP canonical signalling in EC, by driving the SMAD1 pathway
while repressing the SMAD2/3 pathway to protect EC from
EndMT.
ERG promotes SMAD1 whilst repressing SMAD2/3 signalling
in EC. To assess whether ERG inversely regulates SMAD1 and
SMAD2/3 transcriptional activity, we used a SMAD1-dependent
BMP Response Element luciferase reporter (BRE reporter)29 and
a SMAD2/3-dependent SMAD-Binding Element luciferase
reporter (SBE reporter)30. The SMAD2/3 activator TGFβ2
induced enhanced transactivation activity of the SBE reporter
(Supplementary Fig. 3A), with comparable effects at 1 and 10 ng
ml−1 TGFβ2. All following experiments were carried out with
10 ng ml−1 TGFβ2, in line with previous in vitro studies on
EndMT31, 32. Ligand specificity of BMP9 (1 ng ml−1) and TGFβ2
(10 ng ml−1) was shown by selective induction of their target
genes ENG and CNN1, respectively (Supplementary Fig. 3B). In
control siRNA transfected cells, treatment with BMP9-induced a
robust BRE-, but no SBE-mediated signal, whilst TGFβ2 induced
the opposite response, as expected (Fig. 2a, b). Inhibition of ERG
expression caused a significant reduction in SMAD1-dependent
BRE transactivation following BMP9 treatment (Fig. 2a); this was
paralleled by decreased phosphorylation of SMAD1 in response
to BMP9 (Supplementary Fig. 3C) and TGFβ2 (Supplementary
Fig. 3D; quantified Supplementary Fig. 3E), suggesting that ERG
regulates SMAD1 levels and activity. Notably, ERG over-
expression did not further enhance BMP9-induced BRE reporter
transactivation activity (Fig. 2c). TGFβ2 induced a modest
increase in SBE reporter transactivation, which was significantly
enhanced following the deletion of ERG by siRNA (Fig. 2b).
Conversely, ERG-overexpression completely inhibited TGFβ2-
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induced SBE reporter transactivation (Fig. 2d). Basal phosphor-
ylation of SMAD3 was increased in ERG-deficient HUVEC
compared to control (Supplementary Fig. 3D, F, G). These data
indicate that ERG promotes SMAD1 expression and activity,
while repressing SMAD2/3 activity through a
non-transcriptional mechanism (Fig. 2e).
To investigate whether ERG modulation of SMAD2/3 activity
was mediated by the formation of a regulatory complex, we
assessed protein interaction by co-Immunoprecipitation (Co-IP)
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and proximity ligation assay (PLA). Co-IP revealed that ERG
interacts with SMAD3 in HUVEC (Fig. 2f, Supplementary
Figs. 4A, 5B) and in Hepatic Sinusoidal Endothelial Cells (HSEC;
Fig. 2g) isolated from transplant patients with end-stage liver
disease. Interestingly, ERG was found to also bind to SMAD2
(Fig. 2f), while no complex formation was observed with SMAD1
in either cell type (Fig. 2f and Supplementary Fig. 4A). TGFβ2
treatment resulted in the phosphorylation and translocation of
SMAD3 into the nucleus of both HUVEC (Supplementary
Fig. 4B) and HSEC (Supplementary Fig. 4C). This was paralleled
by increased ERG/pSMAD3 complex formation assessed by Co-
IP (Fig. 2f; Supplementary Fig. 4A). PLA confirmed that TGFβ2
treatment induces ERG-pSMAD3 interaction within the nucleus
of HUVEC (Fig. 2h) and ERG-SMAD3 in both cell types
(Supplementary Fig. 4D); no co-localisation was observed
between ERG and SMAD1 (Supplementary Fig. 4D; controls
Supplementary Fig. 4E). Inhibition of SMAD2/3 phosphorylation
by pretreatment with SB-431542 prevented ERG-SMAD3 com-
plex formation (Fig. 2f), suggesting that this interaction is
dependent on SMAD3 phosphorylation. Selective removal of
nucleic acids with benzonase treatment from the protein lysates
(Supplementary Fig. 5A) did not significantly de-stabilise this
interaction (Supplementary Fig. 5B), suggesting that the ERG-
SMAD3 interaction can be maintained in the absence of DNA.
Notably, SB-431542 normalised the enhanced expression of
SMAD3-target genes TGFβ2 and CNN1 in ERG-deficient
HUVEC (Fig. 2i) and HSEC (Fig. 2j), indicating that the EndMT
phenotype in ERG-deficient EC is dependent on SMAD2/3
activity. Thus, these data demonstrate that ERG inhibits SMAD2/
3 activity by direct interaction and formation of an inhibitory
complex.
ERG regulates SMAD3-DNA binding to repress SMAD3
activity. Bio-informatic analysis of ERG-repressed-SMAD2/3-
driven target genes TGFβ2 and CNN1 revealed the presence of
highly conserved ERG DNA binding motifs, upstream of the
transcription start site (TSS), which aligned with histone marks
for active promoter regions, namely H3K4Me3, H3K27Ac,
H3K9Ac and RNA polymerase II (RNA Pol2) occupancy [from
Encyclopaedia of DNA Elements (ENCODE)] (Fig. 3a, b). We
investigated binding of ERG and SMAD3 to these regions, which
also contain several SMAD consensus motifs (Supplementary
Fig. 6A, B). Chromatin immunoprecipitation (ChIP)-qPCR
showed that in unstimulated HUVEC both ERG (Fig. 3c) and
SMAD3 (Fig. 3d) are significantly enriched on the promoters of
TGFβ2 and CNN1. TGFβ2 stimulation significantly reduced ERG
enrichment (Fig. 3c) with concurrent increase in SMAD3
enrichment (Fig. 3d). ERG siRNA treatment led to the loss of
ERG enrichment, as expected (Fig. 3e) and resulted in a sig-
nificant increase in the binding of SMAD3 to the promoters of
both target genes (Fig. 3f). These data indicate that ERG inhibits
SMAD3 binding to DNA at these target gene promoters (model
in Supplementary Fig. 6C).
Erg-deficient mice undergo EndMT and liver fibrogenesis.
To determine whether the loss of endothelial ERG expression
could influence tissue fibrogenesis in vivo, we assessed tissues
from EC-specific constitutive Erg hemi-deficient mice (ErgcEC-Het)
23 and EC-specific inducible Pdgfb-iCreER-eGFP/Ergfl/fl mice
(ErgiEC-KO; genotype data in Supplementary Fig. 7A, B). Increased
collagen deposition and elevated SMA expression was most
pronounced in the liver of both transgenic lines (Fig. 4a). We
observed that reduction or deletion of EC-Erg in both strains
caused disrupted portal tracts (schematic Fig. 4b), with sig-
nificantly increased peri-portal collagen deposition (Fig. 4c) and
SMA expression (Fig. 4d; quantification Fig. 4e, f; each genotype
was compared to Ergfl/fl). Lineage tracing in Erg iEC-KO mice
revealed eGFP+SMA+ EC (Fig. 4g, arrow), a sign of spontaneous
EndMT, which was confirmed by quantification of CD31+SMA+
double positive cells (representative image Supplementary
Fig. 7C, open arrows; quantified in Fig. 4h).
Activation of SMAD3 signalling was observed in the liver
endothelium in Erg-deficient lines, corresponding to the in vitro
results. pSMAD3 staining, undetectable in littermate control
samples, was increased in both ErgcEC-het and Erg iEC-KO mice
(Fig. 5a, b), in EC as well as surrounding tissue. This was
accompanied by proliferation of biliary cells, detected by Ki67
expression, a sign of tissue dysfunction (Supplementary Fig. 7C,
D). These data suggest that loss of EC-ERG induces both
autocrine and paracrine responses through SMAD3 activation. In
parallel with the in vitro studies (Fig. 2i, j), systemic adminis-
tration of the ALK5 inhibitor SB-431542 abolished spontaneous
SMAD3 phosphorylation in ErgcEC-het mice (Supplementary
Fig. 8A). Furthermore, in vivo SB-431542 treatment normalised
TGFβ2 expression in isolated primary mouse EC (Fig. 5c) and
normalised both SMA expression (Fig. 5d, e) and collagen
deposition (Fig. 5f and Supplementary Fig. 8B) compared with
vehicle (DMSO)-treatment in Erg iEC-KO mice. These data show
that loss of endothelial ERG expression causes enhanced SMAD3
activity in both EC and surrounding tissue, resulting in
spontaneous EndMT and a pro-fibrotic microenvironment within
the liver.
Loss of ERG in murine and human fibrotic liver disease. The
finding of spontaneous EndMT and fibrogenesis in Erg-deficient
mice led us to investigate whether endothelial ERG plays a role in
the pathophysiology of liver fibrosis, using a carbon tetrachloride
(CCL4)-induced mouse model. Chronic administration of CCL4
for 8 weeks resulted in characteristic bridging fibrosis (Supple-
mentary Fig. 9A), increased SMA (Fig. 6a, b) and pSMAD3
expression (Supplementary Fig. 9B) in peri-portal areas. Chronic
CCL4 treatment caused loss of ERG expression in all EC, which
was partially restored following an additional 3-week recovery
period (Fig. 6a, c). ERG expression is downregulated by inflam-
matory stimuli such as TNF-α26 and LPS27. As elevated inflam-
matory cytokines are associated with fibrogenesis, we assessed the
impact of TNF-α inhibition on ERG expression (Fig. 6d) and
Fig. 1 Differentially expression of canonical TGFβ/BMP-SMAD genes in ERG-deficient HUVEC. a Microarray analysis of ERG-dependent genes in HUVEC
was performed at 24 and 48 h after ERG depletion, as described (n= 3 biological replicates)24; fold change (log 2) of selected TGFβ/BMP associated genes
represented as high (red) and low (blue) expression compared to the median (white). Gene expression data were validated in HUVEC transfected with
Control (Con siRNA) or ERG siRNA by b quantitative PCR and c immunoblotting, showing reduction of ERG protein levels following siRNA, d quantification
by fluorescence intensity normalised to GAPDH for ERG, SMAD1, ENG, ID1, SMAD3, ALK5 and SMA (n= 5). e Representative images of SMAD1
expression (white; arrows identify expression in the sinusoidal endothelium), VWF (green), SMA (red) and DAPI (blue) in liver tissue from Ergfl/fl and
ErgcEC-het mice (Scale bar 50 μm). f Quantitative analysis of TGFβ2 protein expression was performed by ELISA in whole cell HUVEC lysates (n= 7).
g Representative image of TGFβ2 expression in HUVEC transfected with control or ERG siRNA by immunofluorescence; nuclei are identified by DRAQ V
and cells are co-stained for ERG (green). Scale bar 20 µm. h Representative images of TGFβ2 expression (white; arrows) in large vessel within the liver
from Ergfl/fl and ErgcEC-het mice (Scale bar 50 μm). Data were normalised to GAPDH and compared to control siRNA treated (*) by unpaired t-test. All
graphical data are mean± s.e.m., *P< 0.05, **P< 0.01, ***P< 0.001
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SMAD3 activity (Fig. 6e) by co-administration of the TNF-α
antagonist etanercept in an acute CCL4-induced liver injury. A
single CCL4 injection caused a significant increase in SMA
(Fig. 6f), reduction of ERG expression (Fig. 6g) and enhanced
phosphorylation of SMAD3 at 48 h (Fig. 6h and Supplementary
Fig. 9B); co-administration of etanercept significantly
reduced CCL4-induced SMA expression (Fig. 6f), normalised
endothelial ERG expression (Fig. 6g) and reduced phosphoryla-
tion of SMAD3 (Fig. 6h and Supplementary Fig. 9C). However,
etanercept was unable to correct the CCL4-induced injury in
ErgcEC-het mice (Fig. 6i), with no normalisation of transcriptional
target genes (Fig. 6j) or SMA expression in the liver (Fig. 6k).
15
20
25
30 CON siRNA + SB-431542
ERG siRNA
**
## ###
ERG siRNA + SB-431542
**
***
***
** **
H
S
E
C
0
2
3
1
*
##*
**
ERG
Total SMAD1
ERG IP
IgG
Total SMAD2
IgG
pSMAD3
PB
S
TG
Fβ2
SB
43
15
42
M
ar
ke
r
In
pu
t
Un
bo
un
d
Ig
G
PB
S
TG
Fβ2
SB
43
15
42
Total SMAD3
IgG
IgG
HSEC
pSMAD3
Total SMAD3
IgG
IgG
In
pu
t
Ig
G
PB
S
PBS
Zoom Zoom
Total cell lysate
50
76
50
76
50
76
50
76
50
ERG & pSMAD3
50
76kDa
50
76
TGFβ2
1
1.5
0.0
0.5
2.0
F
ol
d 
ch
an
ge
 c
om
pa
re
d
to
 c
on
tr
ol
 s
iR
N
A
(n
or
m
al
is
ed
 to
 G
A
P
D
H
)
H
U
V
E
C
F
ol
d 
ch
an
ge
 c
om
pa
re
d
to
 c
on
tr
ol
 s
iR
N
A
(n
or
m
al
is
ed
 to
 G
A
P
D
H
)
CNN1TGF2ERG CNN1TGF2ERG
f g
h
i j
0
1
2
3
4
5
6
7
8
9 ***
**
0
1
2
3
4
5
##
TGFβ2
BRE reporter
0
1
2
3
4
5
6
7
8
9
**
***
##
BMP9
SBE reporter
0
1
2
3
4
5
6 ***
***
BRE reporter SBE reporter
Homeostasis EndMT
SMAD3SMAD1
ERG
R
at
io
 lu
c/
re
ni
lla
 n
or
m
al
is
ed
to
 e
ac
h 
P
B
S
 tr
ea
te
d 
ve
ct
or
R
at
io
 lu
c/
re
ni
lla
 n
or
m
al
is
ed
to
 e
ac
h 
P
B
S
 tr
ea
te
d 
ve
ct
or
R
at
io
 lu
c/
re
ni
lla
 n
or
m
al
is
ed
to
 e
ac
h 
P
B
S
 tr
ea
te
d 
ve
ct
or
R
at
io
 lu
c/
re
ni
lla
 n
or
m
al
is
ed
to
 e
ac
h 
P
B
S
 tr
ea
te
d 
ve
ct
or
EV
 C
on
 si
RN
A
EV
 E
RG
 si
RN
A
BR
E 
Co
n 
siR
NA
BR
E 
ER
G 
siR
NA
EV
 C
on
 si
RN
A
EV
 E
RG
 si
RN
A
BR
E 
Co
n 
siR
NA
BR
E 
ER
G 
siR
NA
EV
 C
on
 si
RN
A
EV
 E
RG
 si
RN
A
SB
E 
Co
n 
siR
NA
SB
E 
ER
G 
siR
NA
EV
 C
on
 si
RN
A
EV
 E
RG
 si
RN
A
SB
E 
Co
n 
siR
NA
SB
E 
ER
G 
siR
NA
TGFβ2
BMP9
TGFβ2
EV
 p
cD
NA
EV
 E
RG
3
BR
E 
pc
DN
A
BR
E 
ER
G3
EV
 p
cD
NA
EV
 E
RG
3
SB
E 
pc
DN
A
SB
E 
ER
G3
a b
c d
e
###
BMP9
***
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01169-0 ARTICLE
NATURE COMMUNICATIONS |8:   895 |DOI: 10.1038/s41467-017-01169-0 |www.nature.com/naturecommunications 5
These data suggest that the TNF-α antagonist protects from
CCL4-induced tissue injury through the endothelial ERG path-
way, and reveal that ERG expression is an early, sensitive marker
of vascular inflammation during liver fibrogenesis, which can be
modulated by clinically relevant therapies.
Finally, to verify the relevance of this pathway in human
diseases associated with fibrosis, we obtained liver tissue samples
from end-stage liver transplant patients with alcoholic liver
disease (ALD), non-alcoholic steato-hepatitis (NASH) or primary
biliary cirrhosis (PBC); non-fibrotic tissue from separate donors
was used as control. Liver sections were profiled by immuno-
fluorescence microscopy for CD31, SMA and ERG expression
(Fig. 7a). In non-fibrotic human liver samples, ERG was
expressed in both vascular and sinusoidal EC, with characteristic
nuclear localisation (Supplementary Fig. 10A, B). ERG expression
was significantly decreased in CD31+ EC from ALD and PBC
patient samples compared to non-fibrotic liver samples; in
samples from NASH patient the decrease in EC-ERG expression
did not reach significance (Fig. 7b; additional images provided in
Supplementary Fig. 11A–D). EndMT, identified by CD31+SMA+
double positive cells, was identified in liver fibrosis associated
with ALD and PBC but not in NASH patients (Fig. 7c). Analysis
of CD31+SMA+ co-localisation with ERG expression in all patient
samples revealed a significant negative correlation between ERG
expression and EndMT (Fig. 7d). Therefore, loss of ERG
expression appears to be a sensitive marker of inflammatory-
driven fibrogenesis and could represent a novel biomarker for
EndMT in human fibrotic liver.
Discussion
In this study, we report that the endothelial transcription factor
ERG controls the homoeostatic balance of TGFβ/BMP canonical
signalling in vitro and in vivo; loss of endothelial ERG results in
EndMT and spontaneous liver fibrosis in mouse models and
inversely correlates with EndMT and liver fibrosis in patients.
Expression profiling of ERG-deficient HUVEC identified dys-
regulation of genes involved in SMAD1 and SMAD2/3 signalling.
Expression of EC-restricted genes SMAD1 and its co-receptors
ACVRL1 and ENG was reduced in ERG-deficient HUVEC, in line
with the previous report of ENG as a direct ERG target33.
Mutations in ACVRL1 and ENG cause hereditary haemorrhagic
telangiectasia (HHT), a disease characterised by vascular
malformations34, 35, in agreement with the model that this arm of
the BMP/TGFβ pathway is required for vascular homoeostasis.
Our data reveal that loss of ERG expression significantly affects
SMAD1 phosphorylation and transcriptional activity. Co-IP and
PLA assays revealed that ERG does not interact with SMAD1,
suggesting that ERG is primarily required for the expression of
key proteins in the SMAD1 pathway.
In ERG-deficient EC, loss of SMAD1-dependent transcription
was accompanied by enhanced expression of SMAD2/3 target
genes, indicating an inverse relationship between ERG and
SMAD2/3-dependent targets. This shift in SMAD signalling is
consistent with an EndMT phenotype, characterised by the loss of
EC identity and the emergence of a mesenchymal gene expression
profile9, 10, 13. We demonstrate that ERG directly represses
SMAD2/3 transcriptional activity, independently of expression of
SMAD2/3 or its receptor ALK5. We find that ERG can interact
with SMAD2/3 in HUVEC and in HSEC in agreement with
studies that show overexpression of exogenous ERG and SMAD3
results in protein interaction36, 37. ERG and SMAD3 both bind
to the promoters of target genes, indicating that ERG acts as a
co-repressor for SMAD3. These data are in line with a study
mapping SMAD2/3 global DNA binding in keratinocytes, which
revealed that ETS motifs are represented in ~50% of SMAD-
enriched genes38, suggesting that ETS/SMAD dual motifs may be
important in the regulation of TGFβ/SMAD signalling.
Previous work investigating the regulation of TGFβ/BMP sig-
nalling by ERG in vivo has focused on developmental biology.
ERG was shown to be involved in endocardial-mesenchymal
transition in cardiac valve morphogenesis39 and for TGFβ-
mediated differentiation of sclerotome cells during vertebrae bone
development36. Here we utilised two EC-specific Erg-deficient
mouse strains to assess the role of ERG in regulating SMAD
signalling in post-natal liver physiology; this is the first study to
identify ERG expression in liver vascular and sinusoidal EC. Both
strains displayed deformation of portal tracts with increased
collagen deposition, SMA and pSMAD3 expression confirming a
pro-fibrotic phenotype. Furthermore, analysis of CD31+SMA+
double positive EC and lineage tracing indicates that Erg-deficient
EC undergo spontaneous EndMT in vivo, which was dependent
on SMAD3, as shown by rescue of the phenotypes with
SB-431542. Interestingly, endothelial ERG deficiency caused
enhanced pSMAD3 not only in the endothelium, but also in the
surrounding tissue. Thus, these data suggest that ERG is central to
EC-specific regulation of SMAD2/3 and promotes tissue homo-
eostasis by preventing a paracrine TGFβ2-SMAD3 positive
feedback loop, resulting in a pro-fibrotic tissue
microenvironment.
In a murine model of acute and chronic CCL4-induced liver
fibrosis, we observed a rapid, marked and persistent reduction in
ERG expression. Notably, ERG expression was partially restored
in recovering tissue (3 weeks after terminating chronic CCL4
administration) and protected by co-administration of the TNF-α
inhibitor etanercept. By profiling ERG expression in human liver,
we found marked loss of ERG expression in end-stage liver tissues
from ALD and PBC patients. These diseases have been associated
with inflammatory pathways40, 41. Loss of ERG expression could
be due to chronic vascular inflammation; a similar observation
Fig. 2 ERG differentially regulates transcriptional activity of SMAD1 and SMAD3. ERG-dependent regulation of SMAD1 and SMAD3 activity were assessed
by transactivation assays using either SMAD1 reporter pGL3-BRE (BRE reporter, a and c) or SMAD3 reporter pBV-SBE4 (SBE reporter, b and d). HUVEC
were either co-transfected with Control siRNA (Con siRNA) or ERG siRNA for 24 h (a and b) or with pcDNA or ERG3 overexpression construct (ERG3)
(c and d) prior to treatment with TGFβ2 (red) and BMP9 (blue) or PBS (dashed line) for 18 h (data from pooled HUVEC in triplicate experiments). The ratio
of luciferase to renilla from each transfection was normalised to PBS-treated control or to groups co-transfected with (a and b) Con siRNA or (c and d)
pcDNA (n= 3). e Schematic of the inverse regulation of SMAD1 and SMAD3 by ERG. f Protein−protein interactions between ERG, SMAD1, SMAD2 and
SMAD3 were assessed by Co-IP assay in whole cell lysate from HUVEC. SB-431542 (SB; 10 μM) treatment was performed for 1 h and TGFβ2 (10 ngml−1)
or PBS treatments were performed 30min prior to lysis. Lysates were immunoprecipitated with mouse IgG or mouse α-ERG and then immuno-blotted for
α-ERG, α-SMAD1, α-SMAD2, α-SMAD3 and α-pSMAD3 (Ser423/425). Images representative of four experiments. g ERG-SMAD3 interaction was
assessed by Co-IP in untreated HSEC. h Cellular localisation of the interaction between ERG with pSMAD3 was investigated by Proximity Ligation Assay
(PLA) following 30min TGFβ2 treatment in HUVEC (n= 2). i HUVEC or j HSEC were pre-treated with SB-431542 or DMSO prior to transfection with
either control siRNA or ERG siRNA for 48 h and analysed by qPCR (n= 3). Data were normalised to GAPDH and compared to control siRNA treated (*) or
to ERG siRNA treated with DMSO (#) by unpaired t-test. All graphical data are mean± s.e.m., * or #P< 0.05, ** or ##P< 0.01, *** or ###P< 0.001
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was reported in the endothelium overlaying human athero-
sclerotic plaques26. Anti-TNF therapy has been effective in pre-
clinical liver fibrosis models42, 43; furthermore, etanercept has
shown some efficacy in a case study of PBC associated with
rheumatoid arthritis44. Since ERG expression can be down-
regulated by inflammatory agents, it is likely that inflammation
plays a key role in the loss of ERG expression in these patients.
Interestingly, etanercept could restore ERG expression and reduce
SMAD3 activity in the in vivo model of CCL4-induced liver
fibrosis in wild-type mice, but was ineffective in ErgcEC-het mice,
suggesting that anti-TNF therapies exert a beneficial effect by
restoring endothelial homoeostasis through the ERG pathway.
In conclusion, our findings identify ERG as a novel EC-specific
regulator of canonical TGFβ/BMP, promoting EC-dependent
tissue homoeostasis. We provide evidence that loss of ERG
expression is an early, causative event during liver fibrogenesis.
We describe EndMT in human liver disease, which showed
pathological differences between ALD, PBC and NASH patients.
Therefore, we propose that ERG may represent a sensitive tissue
biomarker to monitor vascular dysfunction and influence ther-
apeutic strategies.
Methods
Cell culture. Primary HUVEC were collected from umbilical cords using
0.5 mg ml−1 Collagenase dissolved in HBSS warmed to 37 °C. Isolated cells were
cultured in M199 media supplemented with Endothelial cell growth supplement
(Sigma) and 20% bovine calf serum22. Hepatic sinusoidal endothelial cells (HSEC)
were isolated from ∼30 g human liver tissue obtained from explanted livers col-
lected from patients in the Liver Unit at Queen Elizabeth Hospital in Birmingham
with informed consent and ethics committee approval. HSEC were then cultured in
medium composed of human endothelial basal growth medium (Invitrogen), 10%
AB human serum (HD Supplies), 10 ng ml−1 vascular endothelial growth factor
(VEGF), and 10 ng ml−1 hepatocyte growth factor (HGF) (PeproTech). Human
ERG expression was repressed by transfection of cells with 20 nM siRNA against
ERG exon 6 (Qiagen; 5′-CAGATCCTACGCTATGGAGTA-3′) or a second siRNA
(#2) targeting exon 7 (Invitrogen; 5′-ACTCTCCACGGTTAATGCATGCTAG-3′)
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Fig. 4 ERG-deficient mouse displays spontaneous liver fibrogenesis surrounding portal tracts. a EC-specific constitutive Erg hemi-deficient (ErgcEC-het) and
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500 µm). Portal tract regions are identified by white asterisk with components depicted schematically in b. Portal tracts were assessed by c H&E and picro-
sirius (red) (Scale bar 20 µm). d Immunofluorescence for SMA (grey scale; red in merge), ERG (white), DAPI (blue) and merged (Scale bar 20 µm). Images
captured from e ErgcEC-het and f ErgiEC-KO mice were quantified for areas of Picro-sirius red positive tissue, using polarised light, and SMA expression
(3 fields per mouse, n= 3). Scale bar 50 μm. g Co-localisation of SMA and eGFP expression, indicative of EndMT, was observed in ErgiEC-KO mice by
immunofluorescence (double positive cell indicated by arrow in cross-section). h Quantification of CD31+SMA+ double positive cells (three fields per
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of the ERG locus, both are denoted in the text as ERG siRNA. In parallel, an
AllStars Negative Control siRNA (Qiagen) was used.
Pharmacological growth factor in vitro cell treatments. SB-431542 was pur-
chased from Sigma (UK). SMAD3-dependent SMAD-Binding Element (SBE)
reporter (SBE4-Luc) was a gift from Bert Vogelstein (Addgene plasmid #16495)30.
pBV-Luc empty vector, lacking a promoter sequence, was a gift from Bert
Vogelstein (Addgene plasmid #16539) and was used as a control45. BMP response
element (BRE) luciferase reporter (pGL3-BRE Luciferase) was a gift from Martine
Roussel and Peter ten Dijke (Addgene plasmid #45126)29. Human ERG cDNA
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(NCBI Accession NM_182918) was cloned into the mammalian expression vector
pcDNA3.1 (Invitrogen). pGL4.10[luc2] (Promega, Madison, USA) Firefly Luci-
ferase empty vector, lacking a promoter sequence, was used as a control. pGL4.73
[hRluc/SV40] (Promega) Renilla luciferase vector was used as an internal nor-
malisation control in the luciferase assay. HUVEC were transfected with Genejuice
transfection reagent (Merck Chemicals), as recommended. Cells were incubated
with 9 μl of GeneJuice, 1 μg luciferase plasmid and/or 1 μg of expression plasmid
and 1 μg of pGL4-Renilla for 24 h.
Human liver tissue sections. Fibrotic human liver tissue was collected from
patients undergoing liver transplantation surgery at the Queen Elizabeth Hospital
in Birmingham for end-stage liver diseases including non-alcoholic steatohepatitis
(NASH), primary biliary cholangitis (PBC) and alcohol related liver disease (ALD).
Non-fibrotic tissues were used as control. All tissues were accessed with informed
written patient consent and research ethics committee approval provided by the
Human Biomaterials Resource Centre at the University of Birmingham, UK. Tissue
was formalin fixed upon collection from patients and paraffin embedded for
immunohistochemical analysis.
Mice and breeding. A Cre/LoxP strategy was used to develop a constitutive
EC-specific heterozygous deletion of Erg using Tie2-Cre-Ergfl/+ (ErgcEC-Het)23 or an
inducible homozygous deletion of Erg using Pdgfb-iCreER-eGFP/Ergfl/fl mice
(ErgiEC-KO). All experiments with Erg-deficient mice were conducted with age and
gender matched animals at Imperial College London in accordance with the UK
Animals (Scientific Procedures) act of 1986. All animals used were retained on a
C57BL/6 background. Both male and female mice were used for experiments and
were 8–10-weeks old. All experiments were conducted using littermate controls
denoted in the text as Ergfl/fl.
Isolation of mouse lung endothelial cells. Primary mouse lung endothelial cells
were isolated from the lungs of control Ergfl/fl and ErgcEC-het mice. Lungs were
dissociated using GentleMACS C tubes and GentleMACS Dissociator (Miltenyi
Biotec), digested with 0.1% collagenase type I (Invitrogen), and sieved through a 70
μm-pore cell strainer (BD Falcon). Magnetic immunosorting (Dynabeads; Invi-
trogen) was used to select EC by a negative sort for FcγRII/III receptor–positive
macrophages followed by a positive sort for CD31–positive endothelial cells. Cells
were plated in flasks precoated with a mixture of 0.1% gelatin (Sigma) and human
plasma fibronectin (Chemicon) and cultured with EGM-2 media (Lonza).
Carbon Tetrachloride CCL4 liver injury model. C57BL/6 J mice were obtained
from Harlan OLAC LTD or from in-house colonies. Acute hepatic inflammation
was induced using intraperitoneal injections of CCl4 (carbon tetrachloride) (Sigma-
Aldrich). CCl4 was diluted 1:4 with mineral oil, and injected intraperitoneally (i.p)
at a concentration of 1 ml kg−1 (control animals were treated with i.p mineral oil
alone). For chronic models, mice were injected with CCl4 IP bi-weekly for 8 weeks.
Indicated mice were allowed to recover for a further 3 weeks before the livers were
collected. Experiments requiring TNF-α blockade were conducted using etanercept
(10 mg kg−1) (Amgen). Mice were injected with etanercept intravenously (i.v.)
30 min prior to single CCl4 administration, control animals were given PBS alone
and liver tissues collected 48 h post-injection. All CCL4 experiments were con-
ducted at University of Birmingham with experimental procedures undertaken in
6–8-week-old mice and used under procedure in accordance the Animals (Scien-
tific Procedures) Act of 1986.
Immunofluorescence analysis of tissue and HUVEC. Tissues were fixed in 4%
paraformaldehyde for 2 h at room temperature, then transferred to 70% ethanol
prior to being embedded in paraffin. Sections were de-paraffinised with Histoclear,
re-hydrated for hematoxylin and eosin and picro-sirius red or heated to 95 °C for
10 min with DAKO antigen retrieval solution for immunofluorescence staining. All
sections were blocked with 2% BSA prior to incubation with primary antibodies
(listed in Supplementary Table 2).
HUVEC for immunofluorescence and proximity ligation assay (PLA) were
grown on gelatinised coverslips in 12-well plates. Cells were fixed with 4%
paraformaldehyde for 15 min prior to blocking with 3% BSA for 1 h. PLA was
performed by manufacturer’s instructions (Duolink Sigma). Primary antibodies
listed in Supplementary Table 2. All tissue sections and HUVEC were mounted
with Prolong Diamond (Molecular Probes) and allowed to dry overnight before
imaging. Confocal microscopy was carried out on a Carl Zeiss LSM780. Images
were analysed with ImageJ (NIH) and Volocity software (PerkinElmer).
Immunoblotting analysis. CelLytic reagent (Sigma), supplemented with 1 mM
phenylmethylsufony fluoride (PMSF) protease inhibitor cocktail and phosphatase
inhibitor cocktail 2 and 3 (Sigma), was used to obtain whole cell protein lysates.
Immunoblots were probed with the primary antibodies detailed in Supplementary
Table 2. Primary antibodies were detected using fluorescently labelled secondary
antibodies: goat α-rabbit IgG DyLight 680 and goat α-mouse IgG Dylight 800
(Thermo Scientific). Odyssey CLx imaging system (LI-COR Biosciences) and
Odyssey 2.1 software was used for detection and quantification of fluorescence
intensity. HRP-conjugated secondary antibodies were used in some instances for
chemiluminescence detection and protein levels were quantified by densitometry
and normalised against loading controls. Supplementary Fig. 12 for the uncropped
immunoblots.
Immunoprecipitation (Co-IP). HUVECs or HSEC were treated with TGFβ2
(Human TGF-β 2; Peprotech) 10 ng ml−1 for 30 min or SB-431542 (Abcam) 10 µg
ml−1 for 1 h after 4 h serum starvation. Cells were collected in lysis buffer (50 mM
Tris, pH 7.5, 150 mM NaCl, 0.1% Igepal, 1 mM EDTA, 0.25% sodium deox-
ycholate)37 supplemented with 1 mM phenylmethylsufony fluoride (PMSF), pro-
tease inhibitor cocktail, and phosphatase inhibitor cocktail 2 and 3 (Sigma).
Endonuclease treatment was conducted with the addition of 500 units of Benzo-
nase (Sigma-Aldrich, UK) for 1 h at room temperature. After clarification by
centrifugation at 4500×g, 1 mg of total protein cell lysate was incubated with 3 µg of
α-ERG antibody (sc-376293, Santa Cruz) or 3 µg of α-mouse IgG (eBioscience) and
Protein A/G PLUS-Agarose (sc-2003, Santa Cruz Biotechnology) overnight at 4 °C.
Beads with the immune-precipitated complex were washed with lysis buffer three
times prior to denaturing in Laemmli buffer at 95 °C for 5 min. Samples were
loaded on 12% acrylamide gels, transferred to nitrocellulose membranes and
probed with α-ERG (ab133264, Abcam) and α- Phospho SMAD3 (ab52903,
Abcam), α-SMAD3 (9523-S, Cell signalling), α-SMAD2 (86F7, Cell signalling),
α-SMAD1 (9743 S, Cell Signalling) antibodies. HRP-conjugated secondary anti-
bodies were used for chemiluminescence detection and protein levels were quan-
tified by densitometry and normalised against loading controls. See Supplementary
Fig. 13 for the uncropped immunoblots.
Reporter assays. Reporter assays in HUVEC were performed with the Dual-
Luciferase Reporter Assay System (Promega) and a GloMax-Multi + Microplate
Multimode Reader (Promega). Twenty-four hours after co-transfection with the
luciferase reporters and expression plasmids and 18 h after stimulation with human
recombinant BMP9 (1 ng ml−1, Peprotech) or TGFβ2 (10 ng ml−1, Peprotech),
HUVEC were lysed and reporter assays were performed in triplicate. For siRNA
experiments, cells were transfected with 20 nM ERG or control siRNAs and after
24 h transfected with the luciferase reporters and activated with the ligands. The
ratio of luciferase signal to Renilla signal from each transfection was determined to
control for well-to-well variation in transfection efficiency.
Real-time polymerase chain reaction. RNA was extracted from tissues and
HUVEC using the RNeasy kit (Qiagen). Supercript III Reverse Transcriptase
(Invitrogen) was used for first strand cDNA synthesis. Quantitative real-time PCR
was carried out using PerfeCTa SYBR Green Fastmix (Quanta Biosciences) on a
Fig. 6 Etanercept prevents ERG loss during murine liver injury. a C57/B6 mice were injected with mineral oil (vehicle; bi-weekly i.p) or with chronic CCl4
administration (8 weeks, bi-weekly i.p); a third group was subjected to a 3-weeks recovery period following CCL4 administration. Representative
immunofluorescence of liver tissue samples stained for VWF (grey scale, green in merge), SMA (grey scale, red in merge) and ERG (white). Scale bar 50
μm. Quantification of b SMA expression and c ERG expression (three fields per mouse, n= 3). Data were compared to mineral oil controls (*) or to chronic
CCL4 administration (#) by one-way ANOVA and Bonferroni multiple comparison post-test. d Representative immunofluorescence following acute (48 h)
mineral oil, CCL4 or co-administration of etanercept and CCl4. Staining for ERG (white); merged images showing VWF (green), SMA (red) and DAPI
(blue). e pSMAD3 (white; stars); other colours as in d; scale bar 20 μm. f–h: Quantification of f SMA, g ERG and h pSMAD3 expression (three fields per
mouse, n= 3). Data were compared to mineral oil controls (*) or to 48 h CCL4 administration (#) by one-way ANOVA and Bonferroni multiple comparison
post-test. i Co-administration of etanercept and CCL4 for 48 h was able to significantly reduce SMA expression in Ergfl/fl mice while it was ineffective in
ErgcEC-Het mice. Representative immunofluorescence of liver tissue, colour scheme as above. Scale bar 50 μm. j Quantification of SMAD2/3 target gene
expression by qPCR in liver tissue of Ergfl/fl mice injected with etanercept and CCL4 compared to CCL4 alone (*) or ErgcEC-Het treated with etanercept and
CCL4 compared to CCL4 alone (#). k Quantification of SMA expression (three fields per mouse, n= 3). Data analysed by one-way ANOVA and Bonferroni
multiple comparison post-test. All graphical data are mean± s.e.m., * or #P< 0.05, ** or ##P< 0.01, *** or ###P< 0.001
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Bio-Rad CFX96 system. Oligonucleotides used for human and mouse are listed in
Supplementary Tables 3, 4, respectively.
ChIP-qPCR. Chromatin immunoprecipitation (ChIP) was carried out using ChIP-
IT express kit (Active Motif). HUVEC were transfected with ERG or control siRNA
(20 nM, for 48 h) or treated with PBS or TGFβ2 (10 ng ml−1, for 30 min), and
cross-linked for 10 min with formaldehyde (final concentration of 1%). Chromatin
was sheared using a Bioruptor UCD-200 ultrasound sonicator (Diagenode),
resulting in DNA fragments of 500–1000 bp in size. Chromatin was immunopre-
cipitated with 2 μg antibody to ERG (sc-354X, Santa Cruz Biotechnology), SMAD3
(#9523, Cell Signalling) or negative control rabbit IgG (PP64, Chemicon, Millipore)
using protein G magnetic beads (Active Motif). Immunoprecipitated DNA was
then used as template for qPCR using primers specific for genomic loci. Oligo-
nucleotide sequences are listed in Supplementary Table 5.
Bioinformatics analysis. Gene ontology analysis was performed using Database
for Annotation, Visualisation, and Integrated Discovery (DAVID), to identify over-
represented gene ontology categories from microarray data obtained from control
and ERG-deficient HUVEC24. Functional clustering tool within DAVID assigned
group gene associated with TGF signalling with an enrichment score of 1.3 (which
corresponds to P< 0.05). Microarray data are deposited in GEO database:
GSE3298424.
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Fig. 7 Loss of ERG expression correlates with EndMT in end-stage human liver disease. a Representative immunofluorescence of human liver sections
stained for SMA (green), CD31 (grey scale; red in merge), ERG (white) and DAPI (blue) were captured from non-fibrotic donor patients with chronic end‐
stage NASH, PBC and ALD with enlarged merge panel. Filled white arrows identify CD31+ERG+ EC whereas empty white arrows show CD31+ERG− EC
(Scale bar 50 µm). b Quantification of SMA, CD31 and ERG expression (five fields per section, n= 4–5). Scale bar 20 μm. Data were compared to
non-fibrotic group (*) by one-way ANOVA and Dunnett’s comparison post-test. c Representative images for CD31 (Red) and SMA (green) staining,
showing co-localisation indicative of EndMT (arrows) and their pixel co-localisation profile in ALD, PBC and NASH patient samples. d Quantification
of pixel co-localisation of CD31 (Red) and SMA (green) by overlap co-efficient was correlated with ERG expression for all individual human section data,
non-fibrotic (black circles), NASH (purple squares), PBC (blue triangle down) and ALD (red triangle up). Correlation was calculated by linear regression,
resulting in a significant negative correlation. All graphical data are mean± s.e.m., *P< 0.05
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The JASPAR database (http://jaspar.genereg.net) was used to identify ERG
transcription factor DNA binding motifs. Data obtained from genome-wide ChIP-
Seq for H3K27ac, H3K4Me3 and H3K4Me1 histone modifications and RNA
polymerase II occupancy in HUVEC and phyloP sequence conservation
(conservation scores between −5 and +5) were based on Multiz alignment analysis
of 100 vertebrate species (derived from the Broad Institute and publicly available
from the ENCODE Consortium). Each track was visualised using the UCSC
Genome Browser database (https://genome.ucsc.edu/index.html).
Statistical analysis. Data shown are representative of at least three experiments
(unless otherwise stated) and are expressed as the mean ± standard error of the
mean (s.e.m.). For in vivo experiments group sizes were determined using estimates
of variance and minimum detectable differences between groups that were
based on our experience of characterising murine phenotypes. Animals were
randomized using an identification numbers, allowing investigators to perform
histological analyses blinded to animal genotype and treatment group. Statistical
significance was determined by Student’s unpaired t-test assuming unequal var-
iances, using Prism 6.0 (Graph Pad). Differences were considered significant with a
P-value< 0.05.
Data availability. The data supporting the findings of this study are available
within the article and its Supplementary Information files and can also be obtained
from the corresponding author upon reasonable request.
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